B
Brii Biosciences
A biotechnology company that commits to bring innovative medicines to China as a way to improve public health
About Brii Biosciences
Brii Bio is a biopharmaceutical startup that specializes in developing innovative treatment options for infectious diseases and central nervous system diseases. The company operates in the healthcare sector, specifically in the pharmaceutical industry, and targets a market segment that includes patients with high unmet medical needs, social stigmas, and limited treatment options.
Read full description
The company's business model is centered around research and development (R&D) of first-in-class and/or different-in-class drugs. In simple terms, first-in-class drugs are those that represent a completely new approach to treating a disease, while different-in-class drugs offer a new or improved version of an existing treatment. This focus on innovation allows Brii Bio to potentially create breakthrough treatments that can command premium pricing in the market.
Brii Bio generates revenue by developing and commercializing these new drugs. Once a drug is developed, it goes through clinical trials and, if successful, is approved for sale. The company then makes money by selling these drugs to healthcare providers and patients.
The company prides itself on its creative and diligent approach to drug development, and is committed to contributing to public health solutions globally. It also places a strong emphasis on its employees, fostering a work culture that supports their health, well-being, and career growth.
At a glance
- Founded
- 2018
- Headquarters
- Durham, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Brii Biosciences.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
ARCH Venture Partners
Sequoia
YunFeng Capital
6 Dimensions Capital
Boyu Capital
Blue Pool Capital
Series B and later3 investors entered at this stage
Invesco
GIC
Lake Bleu Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
20 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Brii Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Brii Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.